

This promotional material is intended for healthcare professionals based in the United Kingdom only.  
This promotional symposium is fully funded and organised by Pierre Fabre Ltd.

[Click here](#) for BRAFTOVI®▼ (encorafenib) prescribing information for Great Britain

[Click here](#) for BRAFTOVI®▼ (encorafenib) prescribing information for Northern Ireland

# Targeting unmet needs in BRAF<sup>V600E</sup> mutant mCRC with targeted therapy: a focus on real-world outcomes with BRAFTOVI®▼ (encorafenib) + cetuximab

Braftovi is indicated in combination with cetuximab, for the treatment of adult patients with mCRC with a BRAF<sup>V600E</sup> mutation, who have received prior systemic therapy<sup>1</sup>



## UK Oncology Forum

Friday 17 June 2022, 13:15–14:00 | International Convention Centre, Belfast

The chair of this session, **Dr Janet Graham**, Consultant Medical Oncologist at The Beatson West of Scotland Cancer Centre, Glasgow, will be joined by **Dr Naureen Starling**, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, London, and **Dr Jenny Seligmann**, Consultant Medical Oncologist at St James's University Hospital, Leeds.

Together, the faculty will:

- **Highlight** the unique biology and poor prognosis of the BRAF<sup>V600E</sup> mutant mCRC patient population.
- **Discuss** ways of ensuring that first treatment decisions can be made to maximise treatment options at all lines of the patient pathway, by referencing overall therapy, targeted therapy, patient monitoring and management.
- **Share** clinical experience of prescribing encorafenib, in combination with cetuximab, for patients with BRAF<sup>V600E</sup> mutant mCRC who have received prior systemic therapy, through case studies and live discussion.

## Agenda (45 mins)

Session	Speaker
Welcome and introduction	Dr Janet Graham
Targeting unmet needs in BRAF <sup>V600E</sup> mutant mCRC with targeted therapy	Dr Jenny Seligmann
Case studies: practical experience with encorafenib and cetuximab	Dr Naureen Starling
Panel discussion and Q&A	ALL
Closing remarks	Dr Janet Graham

We look forward to welcoming you in person to what promises to be an insightful and thought-provoking symposium.

mCRC, metastatic colorectal cancer.

1. Pierre Fabre Ltd. BRAFTOVI (encorafenib) Summary of Product Characteristics.

Pierre Fabre-marketed products will be discussed at this promotional symposium. Any discussion on Pierre Fabre products will be restricted to the terms of the product licence. Pierre Fabre is responsible for the Pierre Fabre-sponsored symposia only. It has not been involved with or had input into the content, agenda or speaker selection of the UK Oncology Forum. Healthcare professionals are recommended to consult the summary of product characteristics at all times.

### Medical information

For Pierre Fabre medical information enquiries please contact:

UK telephone: United Kingdom **0800 0855 292** or by email at: [uk\\_mi@pierre-fabre.com](mailto:uk_mi@pierre-fabre.com)

Adverse events should be reported. In the UK reporting forms and information can be found at the Yellow Card Scheme Website: <https://yellowcard.mhra.gov.uk/> or search for MHRA Yellow Card in Google Play or Apple App Store.

Adverse events should also be reported to Pierre Fabre Ltd.  
Telephone: United Kingdom **0800 0855 292**, or by email at: [uk\\_mi@pierre-fabre.com](mailto:uk_mi@pierre-fabre.com)